ABSTRACT
Leishmaniasis is an infectious disease caused by an intracellular protozoan in humans by 20 different species of Leishmania, among more than 53 species. There are at least 12million cases of infections worldwide and 350 million people are at risk in at least 98 developing countries. Correct diagnosis and characterization of the particular parasite is important for evaluating prognosis and prescribing the appropriate treatment. Leishmaniasis chemotherapy remains very challenging due to the high cost of the drug and its associated toxicity and drug resistance, which develops over a period of time. Many drugs are given to people affected with leishmaniasis but current treatments for visceral leishmaniasis are unsatisfactory because of their toxicity, resistance, and high cost. Many other methods are used to treat leishmaniasis but one of the most promising and leasttoxic treatments is a nanobased treatment for leishmaniasis. The purpose of nanoparticle-based treatment of leishmaniasis to reduce the toxicity and high cost of drugs which are used in leishmaniasis.
